Keros Therapeutics (KROS) Director Charles W. Newton Sells Shares

What Happened
Charles W. Newton, a director of Keros Therapeutics (KROS), sold 551 shares in an open‑market transaction on August 18, 2026. The reported weighted average sale price was $10.30 per share, for aggregate proceeds of $5,675. The shares were sold at prices that ranged from $10.16 to $10.49.

Key Details

• Transaction date: 2026-08-18 (reported on Form 4 filed 2026-08-20). Filing appears timely (within the typical two-business-day Form 4 window).
• Type: Sale (open market/private sale per filing), code S.
• Shares sold: 551; weighted average price: $10.30; total proceeds: $5,675.
• Price range: $10.16–$10.49 (sold in multiple transactions). The reporting person will provide a per-price breakdown on request (footnote).
• Plan: Transactions were made pursuant to a Rule 10b5-1 trading plan adopted March 12, 2026 (footnote).
• Shares owned after the transaction: Not disclosed in the provided filing.

Context
Sales made under a pre-established 10b5-1 plan are typically scheduled in advance and are generally considered less informative about an insider’s current view of the company than opportunistic purchases or unscheduled sales. This was a relatively small dollar-value sale. As always, filings are factual records of transactions and do not by themselves indicate the insider’s motivations.